source
- Osivax shifts to combination strategy after Phase 2b flu vaccine setbackOsivax, a French biotech, reported that its lead influenza vaccine candidate did not meet primary endpoints in a Phase 2b study. The trial, which evaluated the vaccine as a standalone product, sho…
- Argenx halts Phase 3 Sjögren's trial as celiac disease data brings mixed resultsArgenx disclosed on Thursday that it is ending its Phase 3 trial in Sjögren's syndrome after the study failed to meet its primary endpoint. The decision came alongside the release of encouraging r…